Natalizumab and Fatigue: The 'Wearing-Off' Pattern
Natalizumab (Tysabri) is dosed every four (or six) weeks. Users often describe a 'wearing-off' pattern in the last 3–5 days of the cycle: rising fatigue, mild return of prior symptoms, then rapid recovery after infusion.
Key points
- •Wearing-off is reported by roughly a third of natalizumab users.
- •Extended-interval dosing (every 6 weeks) is a common conversation for JCV-positive patients.
- •Objective energy tracking helps your neurology team distinguish wearing-off from disease activity.
What the data shows
Cohort users on natalizumab show a small but reliable dip in the 72 hours before infusion, followed by a same-day recovery.
What to try
- 01Log check-ins around infusion week — the pattern will surface in 2–3 cycles.
- 02Bring your energy trend to your infusion visit.
- 03Discuss JCV index results and dosing interval at every visit.
Frequently asked
Is 'wearing off' the same as a relapse?
No. Wearing off is a temporary, dose-related pattern that resolves with the next infusion. A relapse is new neurological symptoms lasting more than 24 hours and warrants clinical evaluation.
Can extended-interval dosing help?
For JCV-positive patients, extended-interval dosing reduces PML risk. Its impact on wearing-off symptoms varies — track the pattern and discuss with your team.
See your own pattern.
A 60-second daily check-in surfaces the correlations that matter for you — not the average user.
Try Myelina Health freeRelated
Educational content, not medical advice. Always discuss changes to your treatment or routine with your neurology team.